To Örebro University

oru.seÖrebro University Publications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Thromboembolism in Muscle-Invasive Bladder Cancer: A Population-based Nationwide Study
Department of Clinical and Experimental Medicine, Division of Urology, Linköping University, Linköping, Sweden.
Department of Clinical Sciences, Danderyd Hospital, Karolinska Institute, Stockholm, Sweden.
Department of Pelvic Surgery, Karolinska University Hospital, Stockholm, Sweden.
Örebro University, School of Medical Sciences. Örebro University Hospital. Department of Urology.ORCID iD: 0000-0003-4615-5238
Show others and affiliations
2021 (English)In: Bladder Cancer, ISSN 2352-3727, Vol. 7, no 2, p. 161-171Article in journal (Refereed) Published
Abstract [en]

BACKGROUND: Routine VTE prophylaxis within 30 days of radical cystectomy (RC) for urinary bladder cancer (UBC) is used to protect from venous thromboembolism (VTE). However, randomized studies and nationwide population-based studies are lacking.

OBJECTIVE: To study VTE and risk factors for VTE in muscle-invasive UBC in a nationwide population-based series, with a focus on the association with RC with and without chemotherapy.

MATERIALS AND METHODS: We studied all patients with clinical stage T2-T4 UBC diagnosed 1997 to 2014 in the Bladder Cancer Data Base Sweden (BladderBaSe). Previous VTE events and risk factors for VTE were registered from 1987. Cox regression analyses and Kaplan-Meier curves were performed to study risk factors for VTE and cumulative incidence of VTE.

RESULTS: In 9720 patients (71% males) with a median age of 74 years 546 (5.6%) had VTE after diagnosis. In Cox analyses controlling for patient's and tumour characteristics, and risk factors for VTE, VTE after diagnosis and first treatment date were associated with chemotherapy with or without RC. Cumulative incidence of VTE increased during 24 months after diagnosis and first treatment date. VTE were less common in patients with previous cardiovascular disease.

CONCLUSION: VTE was commonly observed after 30 days from diagnosis and from first treatment date in patients with T2-T4 UBC, particularly after chemotherapy. The findings suggest that long-term intervention studies of benefit and possible harms of VTE prophylaxis after UBC should be undertaken.

Place, publisher, year, edition, pages
IOS Press, 2021. Vol. 7, no 2, p. 161-171
Keywords [en]
Bladder cancer, population-based, venous thromboembolism, chemotherapy, cystectomy, prophylaxis
National Category
Cancer and Oncology Clinical Medicine
Identifiers
URN: urn:nbn:se:oru:diva-92477DOI: 10.3233/BLC-200409ISI: 000656306100005Scopus ID: 2-s2.0-85106929050OAI: oai:DiVA.org:oru-92477DiVA, id: diva2:1568869
Funder
Swedish Cancer Society, CAN 2016/470 CAN 2017/278Available from: 2021-06-18 Created: 2021-06-18 Last updated: 2025-02-18Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textScopus

Authority records

Jerlström, Tomas

Search in DiVA

By author/editor
Jerlström, Tomas
By organisation
School of Medical SciencesÖrebro University Hospital
Cancer and OncologyClinical Medicine

Search outside of DiVA

GoogleGoogle Scholar

doi
urn-nbn

Altmetric score

doi
urn-nbn
Total: 44 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf